CN108024966A - 具有受控延迟活性成分释放的制剂 - Google Patents

具有受控延迟活性成分释放的制剂 Download PDF

Info

Publication number
CN108024966A
CN108024966A CN201680053419.0A CN201680053419A CN108024966A CN 108024966 A CN108024966 A CN 108024966A CN 201680053419 A CN201680053419 A CN 201680053419A CN 108024966 A CN108024966 A CN 108024966A
Authority
CN
China
Prior art keywords
active ingredient
release
tablet
propranolol
blend
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680053419.0A
Other languages
English (en)
Chinese (zh)
Inventor
F·鲍尔
T·韦德尔
G·莫德尔莫格
G·比尔克
R·欧吉尼比尼
D·卢布达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN108024966A publication Critical patent/CN108024966A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680053419.0A 2015-09-14 2016-08-25 具有受控延迟活性成分释放的制剂 Pending CN108024966A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15185028.6 2015-09-14
EP15185028 2015-09-14
EP15189045.6 2015-10-09
EP15189045 2015-10-09
PCT/EP2016/001430 WO2017045742A1 (de) 2015-09-14 2016-08-25 Formulierung mit kontrollierter, verzögerter wirkstoffreisetzung

Publications (1)

Publication Number Publication Date
CN108024966A true CN108024966A (zh) 2018-05-11

Family

ID=56855404

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680053419.0A Pending CN108024966A (zh) 2015-09-14 2016-08-25 具有受控延迟活性成分释放的制剂

Country Status (8)

Country Link
US (2) US10874615B2 (https=)
EP (1) EP3349733A1 (https=)
JP (1) JP6841819B2 (https=)
KR (1) KR20180052126A (https=)
CN (1) CN108024966A (https=)
AU (1) AU2016321659A1 (https=)
CA (1) CA2998422A1 (https=)
WO (1) WO2017045742A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160235709A1 (en) 2012-08-31 2016-08-18 Molecular product management LLC Limited release lingual thioctic acid delivery systems
JP7238509B2 (ja) * 2019-03-19 2023-03-14 三菱ケミカル株式会社 医薬錠剤

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359746B1 (en) * 1987-03-25 1992-06-03 E.I. Du Pont De Nemours And Company Use of vinyl alcohol homopolymers and copolymers for tableting active materials
US5838571A (en) * 1996-01-29 1998-11-17 Alza Corporation Tablet press monitoring and controlling method and apparatus
CN1429290A (zh) * 2000-05-12 2003-07-09 伊斯曼化学公司 共聚酯和由其形成的纤维状材料
US7022342B2 (en) * 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
CN1898323A (zh) * 2003-12-19 2007-01-17 伊斯曼化学公司 脂族－芳族共聚酯与乙烯－醋酸乙烯酯共聚物的共混物
CN1898326A (zh) * 2003-12-22 2007-01-17 伊斯曼化学公司 具有改善流变性的可生物降解聚合物的增容共混物
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20110092598A1 (en) * 2007-10-10 2011-04-21 Nandu Deorkar Driectly Compressible High Functionality Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
US20120238644A1 (en) * 2009-11-09 2012-09-20 Glen Gong Fragmented Hydrogels

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58502097A (ja) * 1981-12-18 1983-12-08 キイ・フア−マシユ−テイカルズ・インコ−ポレイテツド ポリビニルアルコ−ルおよびポリエチレングリコ−ルの拡張性格子
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
WO2002003965A1 (en) * 2000-07-06 2002-01-17 Delsys Pharmaceutical Corporation Method for formulating healthcare products with enhanced stability
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
WO2004050066A1 (en) * 2002-11-27 2004-06-17 The University Of Georgia Research Foundation, Inc. Microspheres and related processes and pharmaceutical compositions
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
US9238073B2 (en) * 2006-04-12 2016-01-19 Wyeth Llc Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive
ES2401912T3 (es) * 2008-09-17 2013-04-25 Siegfried Ltd. Granulado que contiene nicotina
JP2013241341A (ja) * 2012-05-17 2013-12-05 Nisshin Kasei Kk マトリックス製剤用基剤、及び該基剤を用いた徐放性製剤
GB201412413D0 (en) * 2014-07-11 2014-08-27 Revolymer Uk Ltd Encapsulated benefit agent particles
WO2016015814A1 (de) * 2014-07-30 2016-02-04 Merck Patent Gmbh Pulverförmige, direkt verpressbare polyvinlalkohol-typen

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359746B1 (en) * 1987-03-25 1992-06-03 E.I. Du Pont De Nemours And Company Use of vinyl alcohol homopolymers and copolymers for tableting active materials
US5838571A (en) * 1996-01-29 1998-11-17 Alza Corporation Tablet press monitoring and controlling method and apparatus
CN1429290A (zh) * 2000-05-12 2003-07-09 伊斯曼化学公司 共聚酯和由其形成的纤维状材料
US7022342B2 (en) * 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
CN1898323A (zh) * 2003-12-19 2007-01-17 伊斯曼化学公司 脂族－芳族共聚酯与乙烯－醋酸乙烯酯共聚物的共混物
CN1898326A (zh) * 2003-12-22 2007-01-17 伊斯曼化学公司 具有改善流变性的可生物降解聚合物的增容共混物
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20110092598A1 (en) * 2007-10-10 2011-04-21 Nandu Deorkar Driectly Compressible High Functionality Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
US20120238644A1 (en) * 2009-11-09 2012-09-20 Glen Gong Fragmented Hydrogels

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROBERT C.DILUCCIO: "Sustained-Release Oral Delivery of Theophylline by Use of Polyvinyl Alcohol and Polyvinyl Alcohol-Methyl Acrylate Polymers", 《JOURNAL OF PHARMACEUTICAL SCIENCE》 *
赵春杰主编: "《药学专业知识（二）2014》", 31 January 2014, 人民军医出版社 *

Also Published As

Publication number Publication date
US20200246270A1 (en) 2020-08-06
JP2018530538A (ja) 2018-10-18
AU2016321659A1 (en) 2018-05-10
JP6841819B2 (ja) 2021-03-10
US10874615B2 (en) 2020-12-29
KR20180052126A (ko) 2018-05-17
WO2017045742A1 (de) 2017-03-23
EP3349733A1 (de) 2018-07-25
CA2998422A1 (en) 2017-03-23
US20190038562A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
JP6706245B2 (ja) 微結晶性セルロースを含む直接圧縮可能な組成物
Abdelkader et al. Formulation of controlled-release baclofen matrix tablets: Influence of some hydrophilic polymers on the release rate and in vitro evaluation
JP2017521471A (ja) 直接圧縮可能なポリビニルアルコール
CN107951853B (zh) 一种盐酸普拉克索缓释药物组合物及其制备方法
EP2217241B1 (en) Wet granulation using a water sequestering agent
Janakiraman et al. Design and evaluation of carvedilol nanocrystals sustained release tablets
US20200246270A1 (en) Formulation having controlled, delayed release of active ingredient
JP5823401B2 (ja) 不快な味が遮蔽された薬物含有膜被覆粒子
Mohammed et al. Formulation and evaluation of mucoadhesive buccal tablet of Anastrozole
CN110381927A (zh) 用于制备具有延长释放的活性药物成分的片剂的直接可压制骨架
JP6855459B2 (ja) 媒体に依存しない活性成分の放出を有する錠剤
JPWO2012091049A1 (ja) 口腔内崩壊錠剤
JP7346404B2 (ja) アカルボースおよびメトホルミンの固定用量組合せ錠剤製剤およびその製造方法
US20230346763A1 (en) Method for preparing solid formulation of pimavanserin
CN100577157C (zh) 含有降血脂成分的分散片及其制备方法
CN118831062B (zh) 一种稳定性好且溶出度高的阿普米司特片及其制备方法
EP2968167A1 (en) Dosage form comprising crizotinib
Trisnaningtyas et al. Formulation of Theophylline Sustained-Release Tablets with a Combination of Eudragit RS 100 and Lactose
Yadav et al. FORMULATION DEVELOPMENT AND IN VITRO EVALUATION OF ORAL DISPERSIBLE TABLETS OF BILASTINE AND MONTELUKAST
Bello Physiochemical and drug release properties of Liquisolid formulations in comparison to their physical mixture counterparts
WO2021148362A1 (en) Directly compressible polymer combinations for matrix tablets with extended drug release
WO2021185804A1 (en) Scored tablet
WO2020249500A1 (en) Stable tablet formulation of nifurtimox and process for producing the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180511